Statement of Need/Program Overview
When and how to use specific direct oral anticoagulant (DOAC) reversal agents is not straightforward. Two major professional societies (eg, the American College of Cardiology [ACC] and the American College of Emergency Physicians [ACEP]) issued expert panel recommendations for anticoagulant reversal only within the last year. In addition, reports of real-world experience with prothrombin complex concentrates (PCCs) for DOAC reversal have been published in the recent past, potentially prompted by familiarity with PCCs to reverse warfarin among other factors. Furthermore, evaluating whether and when to restart anticoagulation therapy is an important part of managing a patient with a DOAC-associated bleed. Join us in this E-monograph activity to explore these topics by a comprehensive review of evidence-based practice guidelines and real-world data around clinical outcomes for DOAC reversal. The goal of this activity is to educate hospital and health-system pharmacists about: (1) updated guidance for using specific DOAC reversal agents in patients with DOAC-associated bleeding, including how to measure patient anticoagulant activity and how to dose specific DOAC reversal agents; (2) emerging data and guidance regarding outcomes and cost with specific DOAC reversal agents and nonspecific PCCs; and (3) recommendations about whether and when to restart anticoagulation therapy after a bleed.
Target Audience
The target audience will be hospital and health-system pharmacists.
Educational Objectives
After completing this activity, the participant should be better able to:
- REVIEW the guidelines for using specific DOAC reversal agents
- EVALUATE emerging data regarding outcomes and cost with specific DOAC reversal agents compared with PCCs
- SUMMARIZE recommendations about whether and when to restart anticoagulation therapy
Faculty
James S. Kalus, PharmD, FASHP
Director of Pharmacy
Henry Ford Health System
Adjunct Assistant Professor of Pharmacy and Medicine
Wayne State University
Detroit, MI
Darius Faison, PharmD, BCPS
Clinical Specialist, Emergency Medicine
Henry Ford Wyandotte Hospital
Wyandotte, MI
SPONSORSHIP & SUPPORT
This educational activity is jointly provided by Global Education Group and Spire Learning.
This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
System Requirement
| PC 1.4 GHz Intel Pentium 4 or faster processor (or equivalent) Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit) 512 MB of RAM (1 GB recommended) Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above) | MAC 1.83 GHz Intel Core Duo or faster processor 512 MB of RAM (1 GB recommended) MAC OS X 10.12, 10.13 and 10.14 Mozilla Firefox, Apple Safari, Google Chrome For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above) |
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
| James S. Kalus, PharmD, FASHP | Nothing to disclose |
| Darius Faison, PharmD, BCPS | Nothing to disclose |
The planners and managers have the following relevant financial relationships with ineligible companies:
| Name of Planner or Manager | Reported Financial Relationship |
| Lindsay Borvansky | Nothing to disclose |
| Andrea Funk | Nothing to disclose |
| Liddy Knight | Nothing to disclose |
| Ashley Cann | Nothing to disclose |
| Andrew Kim | Nothing to disclose |
| Kim Miniter | Nothing to disclose |
| Mary Simmons | Nothing to disclose |
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Spire Learning do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.